natgillin/translations-raw huggingface dataset:
Very rare side effects (may affect up to 1 in 10,000 people): Progressive scarring of lung tissue (interstitial lung disease)**
Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba): Postupni nastanak ožiljaka u tkivu pluća (intersticijska bolest pluća)**
- Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure.
- Hidroklorotiazid pripada skupini lijekova koji se nazivaju tiazidski diuretici, koji uzrokuju povećano izlučivanje urina, što također dovodi do snižavanja Vašeg krvnog tlaka.
In a follow-up trial with the 80 mg/25 mg combination, blood pressure was further decreased (resulting in an overall reduction of 11.5/9.9 mmHg (SBP/DBP).
U ispitivanju praćenja, s kombinacijom 80 mg/25 mg, krvni tlak se nastavio snižavati (što je rezultiralo ukupnim smanjenjem od 11,5/9,9 mmHg (SKT/DKT).
Adverse reactions reported in all clinical trials and occurring more frequently (p ≤0.05) with telmisartan plus hydrochlorothiazide than with placebo are shown below according to system organ class.
Nuspojave prijavljene u svim kliničkim ispitivanjima i one koje se češće javljaju (p ≤ 0,05) uz kombinaciju telmisartana i hidroklorotiazida nego uz placebo prikazane su u nastavku i klasificirane prema organskim sustavima.
Hydrochlorothiazide: Following oral administration of Tolucombi peak concentrations of hydrochlorothiazide are reached in approximately 1.0 - 3.0 hours after dosing.
Hidroklorotiazid: nakon peroralne primjene lijeka Tolucombi, vršne koncetracije hidroklorotiazida postižu se za oko 1,0 - 3,0 sati nakon doziranja.
Tolucombi should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.
Tolucombi ne smije se davati bolesnicima s kolestazom, bilijarnim opstruktivnim poremećajima ili teškom insuficijencijom jetre (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
Tolucombi may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine).
Tolucombi može pojačati učinak snižavanja krvnog tlaka drugih lijekova ili lijekova koji se koriste za snižavanje krvnog tlaka (primjerice baklofen, amifostin).
Tolucombi is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Tolucombi se ne preporučuje u trudnoći te se ne smije primjenjivati kada ste trudni dulje od 3 mjeseca jer može izazvati ozbiljno oštećenje djeteta kada se primjenjuje nakon trećeg mjeseca trudnoće.
Based on modest experience in patients with mild to moderate renal impairment (creatinine clearance of 30 - 60 ml/min, mean about 50 ml/min) no dosage adjustment is necessary in patients with decreased renal function.
Na osnovi skromnog iskustva kod bolesnika s blagim do umjerenim oštećenjem bubrežne funkcije (klirens kreatinina od 30 - 60 ml/min, srednja vrijednost oko 50 ml/min), nije potrebno prilagođavanje doze kod bolesnika sa smanjenom bubrežnom funkcijom.
Tolucombi tablets are for once-daily oral administration and should be taken with liquid, with or without food.
Tolucombi tablete namijenjene su peroralnoj primjeni jednom dnevno te se moraju uzimati s tekućinom, sa ili bez hrane.
- Gout.
- Giht.
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.
Telmisartan premješta angiotenzin II s vrlo velikim afinitetom s njegova mjesta vezivanja na AT1 podtipu receptora, koji je odgovoran za poznata djelovanja angiotenzina II.
The risk of hypokalaemia is greater in patients with cirrhosis of liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or Adrenocorticotropic hormone (ACTH) (see section 4.5).
Rizik od hipokalemije veći je kod bolesnika s cirozom jetre, kod bolesnika koji su imali snažnu diurezu, kod onih koji dobivaju neadekvatan oralni unos elektrolita i kod bolesnika koji su na istodobnom liječenju kortikosteroidima ili adrenokortikotropnim hormonom (ACTH) (vidjeti dio 4.5).
There are no adequate data from the use of Tolucombi in pregnant women.
Ne postoje adekvatni podaci o primjeni lijeka Tolucombi kod trudnica.
- Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists.
- Telmisartan pripada skupini lijekova koji se nazivaju antagonisti receptora angiotenzina II.
If calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.
Ako se moraju propisati nadomjesci kalcija ili lijekovi koji štede kalcij (npr. terapija vitaminom D), moraju se pratiti serumske vrijednosti kalcija te u skladu s time prilagođavati doziranje kalcija.
- Refractory hypokalaemia, hypercalcaemia.
- Refraktorna hipokalemija, hiperkalcemija.
Blisters (OPA/Al/PVC foil//Al foil): 3 years Blisters (OPA/Al/PE foil with desiccant//Al foil): 2 years
Blisteri (OPA/Al/PVC folija//Al folija): 3 godine Blisteri (OPA/Al/PE folija sa sredstvom za sušenje//Al folija): 2 godine
Hypoglycaemia (in diabetic patients)
hipoglikemija (kod bolesnika s dijabetesom)
Experience with Tolucombi is modest in the patients with mild to moderate renal impairment, therefore periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Iskustvo s lijekom Tolucombi je skromno kod bolesnika s blagim do umjerenim oštećenjem funkcije bubrega, stoga se preporučuje periodično praćenje serumskih vrijednosti kalija, kreatinina i mokraćne kiseline.
The elimination half-life is not changed in patients with hepatic impairment.
Poluvrijeme eliminacije je nepromijenjeno kod bolesnika s oštećenjem jetrene funkcije.
Coadministration of lithium and Tolucombi is not recommended (see section 4.4).
Istodobna primjena litija i lijeka Tolucombi se ne preporučuje (vidjeti dio 4.4).
Antidiabetic medicinal products (oral agents and insulin) Dose adjustment of the antidiabetic medicinal products may be required (see section 4.4).
Antidijabetički lijekovi (oralni lijekovi i inzulin) Može biti potrebna prilagodba doze antidijabetičkih lijekova (vidjeti dio 4.4).
Although clinically significant hyperkalaemia has not been documented with Tolucombi, risk factors for the development of hyperkalaemia include renal insufficiency and/or heart failure, and diabetes mellitus.
Iako klinički značajna hiperkalemija nije zabilježena uz Tolucombi, rizični faktori za razvoj hiperkalemije uključuju renalnu insuficijenciju i/ili zatajenje srca te dijabetes melitus.
What you need to know before you take Tolucombi
Što morate znati prije nego počnete uzimati Tolucombi
Patients weighing 58.8 kg or less with hereditary fructose intolerance (HFI) should not take this medicinal product.
Bolesnici s tjelesnom težinom 58,8 kg ili manjom s nasljednim nepodnošenjem fruktoze ne bi smjeli uzimati ovaj lijek.
Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including telmisartan: Baclofen, amifostine.
Na osnovi njihovih farmakoloških svojstava očekuje se moguće potenciranje hipotenzivnih učinaka svih antihipertenzivnih lijekova, uključujući telmisartan, sa sljedećim lijekovima: baklofen, amifostin.
Hydrochlorothiazide:
Hidroklorotiazid:
Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics, including hydrochlorothiazide.
Egzacerbacija ili aktiviranje sistemskog lupus eritematozusa zabilježeno je s primjenom tiazidskih diuretika, uključujući hidroklorotiazid.
The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.
Primarno liječenje je što brži prekid primjene hidroklorotiazida.
Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for Tolucombi.
Povećana učestalost sepse je primijećena samo uz telmisartan, ali ne može se isključiti za Tolucombi.
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Nije bilo dokaza pozitivnih učinaka na kardiovaskularnu smrtnost (omjer rizika 1,03, 95% CI 0,85 - 1,24).
What Tolucombi contains - The active substances are telmisartan and hydrochlorothiazide.
Što Tolucombi sadrži - Djelatne tvari su telmisartan i hidroklorotiazid.
Hypersensitivity, anaphylactic reactions
preosjetljivost, anafilaktičke reakcije
Hydrochlorothiazide may cause or exacerbate hypovolaemia which could lead to electrolyte imbalance (see section 4.4).
Hidroklorotiazid može uzrokovati ili pogoršati hipovolemiju što može dovesti do neravnoteže elektrolita (vidjeti dio 4.4).
Blood creatinine increased, blood creatine phosphokinase increased, hepatic enzyme increased
povišene vrijednosti kreatinina u krvi, povišene vrijednosti kreatin fosfokinaze, povišene vrijednosti jetrenih enzima
Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma.
Hidroklorotiazid, koji je sulfonamid, može uzrokovati idiosinkratičnu reakciju uzrokujući akutnu prolaznu miopiju i akutni glaukom zatvorenog kuta.
Tolucombi should be taken in patients whose blood pressure is not adequately controlled by telmisartan alone.
Tolucombi namijenjen je bolesnicima čiji se krvni tlak ne može adekvatno kontrolirati samo telmisartanom.
Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Može doći do pojave simptomatske hipotenzije, posebno nakon prve doze, kod bolesnika koji imaju smanjen volumen i/ili natrij zbog snažne diuretske terapije, restrikcije unosa soli, proljeva ili povraćanja.
Skin and subcutaneous tissue disorders Not known: Lupus-like syndrome, photosensitivity reactions, skin vasculitis, toxic epidermal necrolysis, erythema multiforme
Poremećaji kože i potkožnog tkiva Nepoznato: sindrom nalik na lupus, reakcije fotoosjetljivosti, vaskulitis kože, toksična epidermalna nekroliza, multiformni eritem
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Omjer rizika za telmisartan naspram ramiprila bio je 1,01 (97,5% CI 0,93 - 1,10, p (za neinferiornost) = 0,0019 na margini od 1,13).
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Stenoza aortalnog i mitralnog zaliska, opstruktivna hipertrofična kardiomiopatija Kao i uz druge vazodilatatore, potreban je poseban oprez kod bolesnika koji pate od aortalne i mitralne stenoze ili opstruktivne hipertrofične kardiomiopatije.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je bilo ispitivanje osmišljeno za testiranje koristi dodavanja aliskirena standardnoj terapiji s ACE inhibitorom ili blokatorom angiotenzin II receptora u bolesnika sa šećernom bolešću tipa 2 i kroničnom bolešću bubrega, kardiovaskularnom bolešću ili oboje.
Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.
Telmisartan blokira učinak angiotenzina II tako što opušta krvne žile i snižava Vaš krvni tlak.
Tolucombi is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet.
Tolucombi je kombinacija dviju djelatnih tvari, telmisartana i hidroklorotiazida, u jednoj tableti.
Children and adolescents The use of Tolucombi in children and adolescents up to the age of 18 years is not recommended.
Djeca i adolescenti Primjena lijeka Tolucombi kod djece i adolescenata ispod 18 godina starosti se ne preporučuje.
Medicinal products used in the treatment for gout (e.g. probenecid, sulfinpyrazone and allopurinol) Dosage adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Lijekovi koji se primjenjuju u liječenju gihta (npr. probenecid, sulfinpirazon i alopurinol) Može biti potrebna prilagodba doze urikozuričnih lijekova s obzirom da hidroklorotiazid može povisiti razinu mokraćne kiseline u serumu.
Hypercalcaemia Very rare: Hypochloraemic alkalosis Not known: Anorexia, appetite decreased, electrolyte imbalance, hypercholesterolaemia, hyperglycaemia, hypovolaemia
hiperkalcemija Vrlo rijetko: hipokloremijska alkaloza Nepoznato: anoreksija, smanjeni apetit, neravnoteža elektrolita, hiperkolesterolemija, hiperglikemija, hipovolemija
** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan.
** Slučajevi postupnog nastanka ožiljaka u tkivu pluća prijavljeni su tijekom unosa telmisartana.
If you experience any of these you should tell your doctor.
Ako osjetite nešto od spomenutog, morate obavijestiti liječnika.
Uncommon: Syncope, paraesthesia Rare:
Manje često: sinkopa, parestezija Rijetko:
Amantadine Thiazides may increase the risk of adverse reactions caused by amantadine.
Amantadin Tiazidi mogu povećati rizik od nuspojava koje uzrokuje amantadin.
Therefore, the use of Tolucombi is not recommended.
Stoga se ne preporučuje primjena lijeka Tolucombi.
The use of Tolucombi during breast feeding is not recommended.
Primjena lijeka Tolucombi tijekom dojenja se ne preporučuje.
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.002.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
U ispitivanju „Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) provedenom na bolesnicima od 50 i više godina starosti, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse uz telmisartan u usporedbi s placebom, 0,70% u odnosu na 0,49% [RR 1,43 (95% interval pouzdanosti 1,00 - 2,06)]; incidencija slučajeva fatalne sepse je povećana za bolesnike koji su uzimali telmisartan (0,33%) u odnosu na bolesnike na placebu (0,16%) [RR 2,07 (95% interval pouzdanosti 1,14 - 3,76)].
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 - 1.5 h after dosing.
Telmisartan: nakon peroralne primjene vršne koncetracije telmisartana postižu se 0,5 - 1,5 h nakon doziranja.
Possible side effects of Tolucombi:
Moguće nuspojave lijeka Tolucombi:
Cholestyramine and colestipol resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
Kolestiramin i kolestipol smole Apsorpcija hidroklorotiazida narušava se prisustvom smola anionske izmjene.
Angioedema (also with fatal outcome), erythema, pruritus, rash, hyperhidrosis, urticaria
angioedem (također s fatalnim ishodom), eritem, pruritus, osip, hiperhidroza, urtikarija
Hydrochlorothiazide In patients taking hydrochlorothiazide alone the following additional side effects have been reported:
Hidroklorotiazid Kod bolesnika koji uzimaju monoterapiju hidroklorotiazida prijavljene su sljedeće dodatne nuspojave:
In preclinical safety studies performed with co-administration of telmisartan and hydrochlorothiazide in normotensive rats and dogs, doses producing exposure comparable to that in the clinical therapeutic range caused no additional findings not already observed with administration of either substance alone.
Pretkliničke studije sigurnosti izvedene s istodobnom primjenom telmisartana i hidroklorotiazida na normotenzivnim štakorima i psima, pri dozama koje dovode do izloženosti usporedivoj s onima u kliničkom terapijskom rasponu nisu dale dodatna otkrića koja već ranije nisu bila primijećena u primjeni svake tvari zasebno.
Somnolence
somnolencija
If you forget to take Tolucombi
Ako ste zaboravili uzeti Tolucombi
Adverse reactions known to occur with each component given singly but which have not been seen in clinical trials may occur during treatment with Tolucombi.
Nuspojave za koje se zna da se pojavljuju sa svakom komponentom zasebno, ali nisu bile primijećene u kliničkim ispitivanjima mogu se pojaviti tijekom liječenja lijekom Tolucombi.
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Osim ako se nastavak terapije antagonistom receptora angiotenzina II ne smatra neophodnim, bolesnice koje planiraju trudnoću moraju prijeći na zamjensko antihipertenzivno liječenje koje ima utemeljen profil sigurnosti za primjenu u trudnoći.
In case of surgery or anaesthetics, you should tell your doctor that you are taking Tolucombi.
Ako trebate na operaciju ili morate primiti anestetik, morate biti sigurni da Vaš liječnik zna da uzimate Tolucombi.
Tolucombi must not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) (see section 4.3).
Tolucombi se ne smije primjenjivati kod bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina <30 ml/min) (vidjeti dio 4.3).
In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo.
U ispitivanju PRoFESS primijećena je povećana incidencija sepse uz telmisartan u usporedbi s placebom.
The concomitant use of Tolucombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Tolucombi s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem funkcije bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II antagonists and diuretics, ATC code:C09DA07.
Farmakoterapijska skupina: Lijekovi koji djeluju na renin-angiotenzinski sustav; antagonisti angiotenzina II s diureticima, ATK oznaka: C09DA07.
Non-steroidal anti-inflammatory medicinal products (NSAIDs) NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and nonselective NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists.
Nesteroidni protuupalni lijekovi (NSAIL-i) NSAIL-i (tj. acetilsalicilatna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL-i) mogu reducirati diuretski, natriuretski i antihipertenzivni učinak tiazidskih diuretika te antihipertenzivni učinak antagonista receptora angiotenzina II.
Blister (OPA/Al/PVC foil//Al foil): 14 x 1 tablet
Blister (OPA/Al/PVC folija//Al folija): 14 x 1 tableta
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics.
Pretpostavlja se da putem blokade sustava renin-angiotenzin-aldosteron, istodobna primjena telmisartana ima tendenciju vraćanja gubitka kalija povezanog s ovim diureticima.
Tolucombi is not indicated in patients with severe hepatic impairment.
Tolucombi nije indiciran kod bolesnika s teškim oštećenjem jetrene funkcije.
Visual disturbance, vision blurred
poremećaj vida, zamućeni vid
Endocrine disorders Not known: Diabetes mellitus inadequate control
Endokrini poremećaji Nepoznato: neodgovarajuća kontrola dijabetes melitusa
Immune system disorders Not known: Anaphylactic reactions, hypersensitivity
Poremećaji imunološkog sustava Nepoznato: anafilaktičke reakcije, preosjetljivost
Do not take Tolucombi: - if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6).
Nemojte uzimati Tolucombi - ako ste alergični na telmisartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako ste alergični na hidroklorotiazid ili neki od drugih derivata sulfonamida.
- The other ingredients are: hydroxypropylcellulose, lactose monohydrate, magnesium stearate, mannitol, meglumine, povidone (K30), red ferric oxide (E172) - only in 40 mg/12.5 mg and 80 mg/12.5 mg tablets, silica colloidal anhydrous, sodium hydroxide (E524), sodium stearyl fumarate, sorbitol (E420) and yellow ferric oxide (E172) - only in 80 mg/25 mg tablets.
- Drugi sastojci su hidroksipropilceluloza, laktoza hidrat, magnezijev stearat, manitol, meglumin, povidon (K30), crveni željezov oksid (E172) - samo u tabletama od 40 mg/12,5 mg i 80 mg/12,5 mg, silicijev dioksid koloidni, bezvodni, natrijev hidroksid (E524), natrijev stearilfumarat, sorbitol (E420) i žuti željezov oksid (E172) - samo u tabletama od 80 mg/25 mg.
Such conditions should be corrected before the administration of Tolucombi.
Takva stanja moraju se korigirati prije primjene lijeka Tolucombi.
If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
Ako se rokovi podnošenja periodičkog izvješća o neškodljivosti (PSUR) podudaraju s nadopunama Plana upravljanja rizikom (RMP), dokumenti mogu biti podneseni istodobno.
In patients with mild to moderate hepatic impairment the posology should not exceed Tolucombi 40 mg/12.5 mg once daily.
Kod bolesnika s blagim do umjerenim oštećenjem jetrene funkcije doza lijeka Tolucombi ne smije prelaziti 40 mg/12,5 mg jedanput dnevno.
No clear evidence of a teratogenic effect was observed, however at toxic dose levels of telmisartan an effect on the postnatal development of the offsprings such as lower body weight and delayed eye opening was observed.
Međutim, pri toksičnim dozama telmisartana, primijećeni su učinci na postnatalni razvoj legla, kao što su smanjena tjelesna težina i odgođeno otvaranje očiju.
Abnormal hepatic function/liver disorder
abnormalna jetrena funkcija/poremećaj jetre
Telmisartan In patients taking telmisartan alone the following additional side effects have been reported:
Telmisartan Kod bolesnika koji uzimaju monoterapiju telmisartana prijavljene su sljedeće nuspojave:
Cytotoxic agents (e.g. cyclophosphamide, methotrexate) Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.
Citotoksični lijekovi (npr. ciklofosfamid, metotreksat) Tiazidi mogu reducirati renalnu ekskreciju citotoksičnih lijekova i potencirati njihove mijelosupresivne učinke.
- Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
- Stenoza bubrežne arterije (sužavanje krvnih žila koje vode u jedan ili oba bubrega).
Toxicological findings also well known from preclinical studies with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists were: a reduction of red cell parameters (erythrocytes, haemoglobin, haematocrit), changes of renal haemodynamics (increased blood urea nitrogen and creatinine), increased plasma renin activity, hypertrophy/hyperplasia of the juxtaglomerular cells and gastric mucosal injury.
Toksikološki nalazi, također dobro poznati iz pretkliničkih studija s inhibitorima enzima koji pretvara angiotenzin i s antagonistima receptora angiotenzina II, bili su: smanjenje parametara crvenih krvnih stanica (eritrociti, hemoglobin, hematokrit), promjene u bubrežnoj hemodinamici (povišeni dušik iz uree u krvi (BUN) i kreatinin), povećana aktivnost renina u plazmi, hipertrofija/hiperplazija jukstaglomerularnih stanica i ozljeda želučane sluznice.